EMITF Elbit Imaging

ELBIT IMAGING ANNOUNCES UPDATE REGARDING THE AGREEMENT TO SELL ITS HOLDINGS IN THE PROJECT IN BANGALORE, INDIA

ELBIT IMAGING ANNOUNCES UPDATE REGARDING THE AGREEMENT TO SELL ITS HOLDINGS IN THE PROJECT IN BANGALORE, INDIA

Tel Aviv, Israel, June 13, 2019 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (TASE, UTC UC: EMITF) ("Elbit" or the "Company") announced today, further to its press release dated March 4, 2019, regarding the termination of the Joint Development Agreement ("JDA") and the Term Sheet between Elbit Plaza India Real Estate Holdings Limited (a subsidiary held by the Company (50%) and Plaza Centers N.V. (50%)) ("EPI") and the  purchaser (the "Purchaser") regarding a 74.7 acre plot in Chennai, India held by an SPV subsidiary of EPI, a transaction with total consideration of INR 108 crores (approximately Euro 13.5 million) (the "Consideration"), that the parties have signed a share purchase agreement ("SPA") according to which:

  1. The Purchaser has paid a deposit of INR 5 crores (approximately Euro 0.625 million) in order to provide the Purchaser with an additional six months to complete the closing, which may be extended by another month upon payment by the Purchaser of an additional deposit of INR of 5 crores. As of this date, the Purchaser has deposited a total of INR 15 crores (approximately Euro 1.875 million) (the "Deposits").
  2. If the Purchaser is unable to complete the closing within the aforesaid time periods, then the parties will mutually appoint an international real estate consulting firm for the purpose of identifying a third-party buyer within a period of six months.
  3. If the Purchaser is unable to complete the closing and no third-party buyer is found within the aforesaid time periods, both the JDA and SPA shall be terminated, subject to the Purchaser receiving the Deposits. However, the Purchaser will not be entitled to reimbursement of expenses incurred by it under the JDA.
  4. Any final price received from a third-party buyer above the Consideration will be shared 67% by the Purchaser and 33% by EPI. The Consideration is subject to adjustment with respect to the Deposits and the existing cash in the SPV.
  5. The Consideration will be remitted in Euro at the base rate already agreed upon by the parties. Foreign exchange loss arising due to change in conversion rate from INR to euro will be borne by the Purchaser and gain will be credited to the account of EPI.
  6. The parties withdraw the arbitration proceedings and other notices. 

At this stage, there is no certainty that the SPA closing will occur.

The information detailed above, concerning the consummation of the transaction to sell the plot in Chennai, India, is a forward-looking statement. Actual results may differ materially from those projected, expressed or implied in the forward-looking statement as a result of various factors including, without limitation, a change in market conditions, disputes with the purchaser, and the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2018, under the caption “Risk Factors”. Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained in our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements, unless required by law.

About Elbit Imaging Ltd.

Elbit Imaging Ltd. operates in the following principal fields of business: (i) medical industries through our indirect holdings in Insightec Ltd. and Gamida Cell Ltd.; and (ii) land in India which is designated for sale (and which was initially designated for residential projects).

For Further Information:

Company Contact 
Ron Hadassi 
CEO and Chairman of the Board of Directors 
Tel:

Fax:
 
 

 

EN
13/06/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Elbit Imaging

 PRESS RELEASE

ELBIT IMAGING ANNOUNCES VOLUNTARY SEC DEREGISTRATION

ELBIT IMAGING ANNOUNCES VOLUNTARY SEC DEREGISTRATION Tel Aviv, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (TASE, OTC US: EMITF) ("Elbit" or the "Company") announced today, that its Board of Directors approved the filing of a Form 15F with the Securities and Exchange Commission ("SEC") to voluntarily deregister its ordinary shares under Section 13(a) and Section 15(d) of the Securities Exchange Act of 1934 (the "Exchange Act"). The Company will file today the Form 15F. The Company's reporting obligations under the Exchange Act will be suspended immediately upon the filing...

 PRESS RELEASE

ELBIT Imaging Announces Update Regarding the Agreement to Sell Its Hol...

ELBIT Imaging Announces Update Regarding the Agreement to Sell Its Holdings In the Project in Bangalore, India TEL AVIV, Israel, July 25, 2019 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (TASE, OTC US: EMITF) ("Elbit" or the "Company") announced today, further to its press release dated May 27, 2019, regarding an agreement (the "Agreement") signed by Elbit Plaza India Real Estate Holdings Limited (a subsidiary held by the Company (50%) and Plaza Centers N.V. (50%)) ("EPI"), for the sale of a 100% interest in a Special Purpose Vehicle which holds a site in Bangalore, India, to a local investor ...

 PRESS RELEASE

ELBIT IMAGING LTD. ANNOUNCES THAT INSIGHTEC RECEIVES FDA APPROVAL AND ...

ELBIT IMAGING LTD. ANNOUNCES THAT INSIGHTEC RECEIVES FDA APPROVAL AND CE MARK FOR EXABLATE NEURO WITH GE SIGNA PREMIER MRI SYSTEM Tel Aviv, Israel, July 10, 2019 (GLOBE NEWSWIRE) --  Elbit Imaging Ltd. (TASE, OTC US: EMITF) ("Elbit" or the "Company") announced today that Insightec Ltd. ("Insightec") announced today FDA approval and CE mark for Exablate Neuro™ compatible with the SIGNA™ Premier MRI system from GE Healthcare. Exablate Neuro has FDA approval for the treatment of medication-refractory essential tremor and tremor-dominant Parkinson's disease and CE mark for the treatment...

 PRESS RELEASE

ELBIT IMAGING ANNOUNCES THAT GAMIDA CELL ANNOUNCES FULL EXERCISE OF UN...

ELBIT IMAGING ANNOUNCES THAT GAMIDA CELL ANNOUNCES FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES Tel Aviv, Israel, July 08, 2019 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (TASE, UTC UC: EMITF) (“Elbit” or the “Company”) announced today, further to its press release dated June 27, 2019 that Gamida Cell Ltd. (Nasdaq: GMDA) (“Gamida”), an indirect shareholding of the Company announced that the underwriters of its recently closed underwritten public offering of 7,000,000 ordinary shares have exercised in full their option to purchase an additional 1,050,000 ordinary shares ...

 PRESS RELEASE

ELBIT IMAGING ANNOUNCES RECEIVING FIRST INTEREST PAYMENT UNDER THE VEN...

ELBIT IMAGING ANNOUNCES RECEIVING FIRST INTEREST PAYMENT UNDER THE VENDOR LOAN GIVEN TO THE RADISSON HOTEL PURCHASER Tel Aviv, Israel, July 03, 2019 (GLOBE NEWSWIRE) -- Elbit Imaging Ltd. (TASE, UTC UC: EMITF) (“Elbit” or the “Company”) announced today, further to its press releases dated December 18, 2017 and April 2, 2019 regarding the sale of its holdings in a SPV that holds the Radisson Hotel Complex in Bucharest, Romania (the "Agreement"), in which the Company has granted to the hotel's purchaser (the "Purchaser") a vendor loan of €8 million (the "Vendor Loan"), that the Purchaser ha...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch